我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

蛋白酶激活受体2与心肌缺血/再灌注损伤

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2018年第4期
页码:
464-468
栏目:
综述
出版日期:
2018-04-25

文章信息/Info

Title:
PAR-2 and myocardial ischemia reperfusion injury
作者:
王 敏; 陈启稚
（上海交通大学附属医学院附属第九人民医院心内科，上海 200011）
Author(s):
WANG Min;  CHEN Qi-zhi
(Department of Cardiovascular Medicine, Nine Hospital Affiliated to School of Medicine, Shanghai Jiaotong University, Shanghai 200011, China)
关键词:
蛋白酶激活受体2; 心肌缺血再灌注损伤; 氧化应激; 中性粒细胞浸润 ; 细胞凋亡
Keywords:
protease activated receptor 2;  myocardial ischemia/reperfusion injury;  oxidative stress;  neutrephil infiltration;  cell apoptosis
分类号:
R542.2
DOI:
-
文献标识码:
A
摘要:
氧化应激、炎症和细胞凋亡在心肌缺血/再灌注损伤(myocardial ischemia/reperfusion injury,MI/RI)中起重要作用，而蛋白酶激活受体（protease-activated receptor，PAR）-2与MI/RI之间存在密切关系。PAR-2广泛分布于心血管系统，可被多种蛋白酶激活，启动多种生物学效应。本文从上述几方面对PAR-2与MI/RI的关系进行阐述，为MI/RI的防治提供理论依据。
Abstract:
Oxidative stress, inflammation and apoptosis play an important role in myocardial ischemia reperfusion injury (MI/RI). There is a close relationship between protease activated receptor-2 (PAR-2) and MI/RI. PAR-2 is widely distributed in the cardiovascular system, which may be activated by many proteases and result in a variety of biological effects. This article aims to explore the relationship from the above aspects and to provide a theoretical basis for prevention and treatment of MI/RI.

参考文献/References

[1]Mozaffarian D,Benjamin EJ,Go AS,et al.Heart disease and stroke statistics-2015 update:a report from the American Heart Association[J].Circulation,2015,131(4):e29-322.

[2]Hausenloy DJ,Yellon DM.Myocardial ischemia-reperfusion injury:a neglected therapeutic target[J].J Clin Invest,2013,123(1):92-100.

[3]Frank A,Bonney M,Bonney S,et al.Myocardial ischemia reperfusion injury:from basicscience to clinical bedside[J].Semin Cardiothorac Vasc Anesth,2012,16(3):123-132.

[4]Napoli C,Cicala C,Wallace JL,et al.Protease-activated receptor-2 modulates myocardial ischemia-reperfusion injury in the rat heart[J].Proc Natl Acad Sci USA,2000,97(7):3678-3683.

[5]Napoli C,De Nigris F,Cicala C,et al.Protease-activated receptor-2 activation improves efficiency of experimental ischemic preconditioning[J].Am J Physiol Heart Circ Physiol,2002,282(6):2004-2010.

[6]Adams MN,Ramachandran R,Yau MK,et al.Structure, function and pathophysiology of protease activated receptors[J].Pharmacol Ther,2011,130(3):248-282.

[7]Yau MK,Liu L,Fairlie DP,et al.Toward drugs for protease-activated receptor 2 (PAR2)[J].J Med Chem,2013,56(19):7477-7497.

[8]Mihara K,Ramachandran R,Saifeddine M,et al.Thrombin-Mediated Direct Activation of Proteinase-Activated Receptor-2:Another Target for Thrombin Signaling[J].Mol Pharmacol,2016,89(5):606-614.

[9]Hollenberg MD,Mihara K,Polley D,et al.Biased signalling and proteinase-activated receptors(PARs):targeting inflammatory disease[J].Br J Pharmacol,2014,171(5):1180-1194.

[10]Suen JY,Cotterell A,Lohman RJ,et al.Pathway-selective antagonism of proteinase activated receptor 2[J].Br J Pharmacol,2014,171(17):4112-4124.

[11]Rothmeier AS,Ruf W.Protease-activated receptor 2 signaling in inflammation[J].Semin Immunopathol,2012,34(1):133-149.

[12]Dutra-Oliveira A,Monteiro RQ,Mariano-Oliveira A.Protease-activated receptor-2(PAR-2)mediates VEGF production through the ERK1/2 pathway in human glioblastoma cell lines[J].0Biochem Biophys Res Commun,2012,421(2):221-227.

[13]Jin G,Hayashi T,Kawagoe J,et al.Deficiency of PAR-2 gene increases acute focal ischemic brain injury[J].J Cereb Blood Flow Metab,2005,25(3):302-313.

[14]Morello S,Vellecco V,Roviezzo F,et al.A protective role for proteinase activated receptor 2 in airways of lipopolysaccharide -treated rats[J].Biochem Pharmacol,2005,71(1 -2):223-230.

[15]Zhou T,Chuang CC,Zuo L,et al.Molecular Characterization of Reactive Oxygen Species in Myocardial Ischemia-Reperfusion Injury[J].Biomed Res Int,2015,1155(10):486-495.

[16]Xia Z,Li H,Irwin MG,et al.Myocardial ischaemia reperfusion injury:the challenge of translating ischaemic and anaesthetic protection from animal models to humans[J].Br J Anaesth,2016,117(2):44-62.

[17]Boag SE,Andreano E,Spyridopoulos I,et al.Lymphocyte Communication in Myocardial Ischemia/Reperfusion Injury[J].Antioxid Redox Signal,2017,26(12):660-675.

[18]Bagheri F,Khori V,Alizadeh AM,et al.Reactive oxygen species-mediated cardiac-reperfusion injury:Mechanisms and therapies[J].Life Sciences,2016,165:43-55.

[19]Michael M Galagudza,Dmitry L Sonin,et al.Remote vs local ischaemic preconditioning in the rat heart: infarct limitation, suppression of ischaemic arrhythmia and the role of reactive oxygen species[J].International Journal of Experimental Pathol ogy,2016,97(1):66-74.

[20]Park GH,Jeon SJ,Ryu JR,et al.Essential role of mitogen-activated protein kinase pathways in protease activated receptor 2-mediated nitric-oxide production from rat primary astrocytes[J].Nitric Oxide,2009,21(2):110-119.

[21]Lim SY,Tennant GM,Kennedy S,et al.Activation of mouse protease-activated receptor-2 induces lymphocyte adhesion and generation of reactive oxygen species[J].Br J Pharmacol,2006,149(5):591-599.

[22]Antoniak S,Rojas M,Spring D,et al.Protease-Activated Receptor 2 Deficiency Reduces Cardiac Ischemia/Reperfusion Injury[J].Arterioscler Thromb Vasc Biol,2010,30(11):2136-2142.

[23]Kleinbongard P,SchulzR,Heusch G.TNFalpha in myocardial ischemia/reperfusion, remodeling and heart failure[J].Heart Fail Rev,2011,16(1):49-69.

[24]Birdsall HH,Green DM,Trial J,et al.Complement C5a,TGF-beta 1,and MCP-1,in sequence,induce migration of monocytes into ischemic canine myocardium within the first one to five hours after reperfusion[J].Circulation,1997,95(3):684-692.

[25]Ferrandi C,Ballerio R,Gaillard P,et al.Inhibition of c-Jun N-terminal kinase decreases cardiomyocyte apoptosis and infarct size after myocardial ischemia andreperfusion in anaesthetized rats[J].Br J Pharmacol,2004, 142(6):953-960.

[26]Kaiser RA, Bueno OF, Lips DJ,et al.Targeted inhibition of p38 mitogen-activated protein kinase antagonizes cardiac injury and cell death following ischemia reperfusion in vivo[J].J Biol Chem,2004,279(15):15524-15530.

[27]Ramachandran R,Hollenberg MD. Proteinases and signalling: pathophysiological and therapeutic implications via PARs and more[J].Br J Pharmacol,2008,153(1):263-282.

[28]Antoniak S,Sparkenbaugh EM,Tencati M,et al.Protease activated receptor-2 contributes to heart failure[J].PLoS One,2013,8(11):81733.

[29]Kalogeris T,Baines CP,Krenz M,et al.Ischemia/Reperfusion[J].Compr Physiol,2016,7(1):113-170.

[30]Jennings RB.Historical perspective on the pathology of myocardial ischemia/reperfusion injury[J].Circ Res,2013,113(4): 428-438.

[31]Badr R,Hashemi M,Javadi G,et al.Assessment of global ischemic/reperfusion and Tacrolimus administration on CA1 region of hippocampus:gene expression profiles of BAX and BCL2 genes[J].Bratisl Med,2016,115(6):358-362.

[32]Moazami-Goudarzi M,Farshdousti-Hagh M,Hoseinpour-Feizi A,et al.The acute lymphoblastic leukemia prognostic scoring whether it is possible by BCL-2,BAX gene promoter genotyping[J].Caspian J Intern Med,2016,7(2): 105-113.

[33]Condorelli G1,Roncarati R,Ross J Jr,et al.Heart-targeted overexpression of caspase3 in mice increases infarct size and depresses cardiac function[J].PNAS,2001,98(17):9977-9982.

[34]Tong XH,Ding JW,Yang J,et al.The effect of protease-activated receptor2 on rat apoptotic cardiomyocytes underwent ischemia reperfusion injury[J].Zhonghua Xin Xue Guan Bing Za Zhi,2009(37):832-836.

[35]Jiang R,Zatta A,Kin H,et al.PAR-2 activation at the time of reperfusion salvages myocardium via an ERK1/2 pathway in in vivo rat hearts[J].Am J Physiol Heart Circ Physiol,2007,293(5):2845-2852.

[36]Nguyen Thi PA,Chen MH,Li N,et al.PD98059 Protects Brain against Cells Death Resulting from ROS/ERK Activation in a Cardiac Arrest Rat Model[J].Oxidative medicine and cellular longevity,2016,2016:3723762.

[37]McLean PG,Aston D,Sarkar D,et al.Protease-activatedreceptor-2 activation causes EDHF-like coronary vasodilation selectivepreservation in ischemia/reperfusion injury:involvement of lipoxygenaseproducts,VR1 receptors,and C-fibers[J].Circ Res,2002,90(4):465-472.

[38]Tennant GM,Wadsworth RM,Kennedy S,et al.PAR-2 mediates increased inflammatory cell adhesion and neointima formation following vascular injury in the mouse[J].Atherosclerosis,2008,198(1):57-64.

[39]Dutra-Oliveira A,Monteiro RQ,Mariano-Oliveira A.Protease-activated receptor-2(PAR2)mediates VEGF production through the ERK1/2 pathway in human glioblastoma cell lines[J].Biochem Biophys Res Commun,2012,421(2):221-227.

[40]Hollenberg MD,K Mihara,Polley D,et al.Biased signalling and proteinase-activated receptors (PARs):targeting inflammatory disease[J].Br J Pharmacol,2014,171(5):1180-1194.

[41]Soh UJ,Dores MR,Chen B,et al.Signal transduction by protease-activated receptors[J].Br J Pharmacol,2010,160(2):191-203.

[42]Freedman NJ,Shenoy SK.Regulation of inflammation by beta-arrestins:Not just receptor tales[J].Cell Signal,2018,41:41-45.

[43]Patel PA,Tilley DG,Rockman HA.Physiologic and cardiac roles of beta-arrestins[J].Mol.Cell Cardiol,2009,46(3):300-308.

备注/Memo

备注/Memo:
收稿日期: 2017-04-12.基金项目：国家自然科学青年基金资助项目（81300087） 通讯作者：陈启稚，副主任医师，主要从事冠心病基础与临床研究 Email：qizhi_chen@126.com 作者简介：王敏，硕士生 Email：minnwang@163.com
更新日期/Last Update: 1900-01-01